Social media

ICON has been named as one of the TIME World's Best Companies in Sustainable Growth 2025. As an organisation that places a great deal of emphasis on #ESG, having our #ICONCares initiative recognised on a global scale i...

ICON has been named as one of the TIME World's Best Companies in Sustainable Growth 2025. As an organisation that places a great deal of emphasis on ESG, having our ICON Cares initiative recognised on a global scale is a...

Last Thursday, colleagues from our Barcelona office came together for the first edition of the ICON Run4Health, organised by our Barcelona Volunteering Team. Team members took part in a 5K run or walk to raise funds for...

Antimicrobial resistance is a growing global threat, making traditional antibiotics less effective. ICON’s latest article explores how bacteriophage therapy—a virus-based approach—could help tackle multidrug-resistant in...

Antimicrobial resistance is a growing global threat, making traditional antibiotics less effective. ICON’s latest article explores how bacteriophage therapy—a virus-based approach—could help tackle multidrug-resistant in...

Everything you need to make the important decision of where to publish your work. 50+ metadata consideration points including deadlines and lead times. Links to author submission guides fast and easy. Request a demo. htt...

Everything you need to make the important decision of where to publish your work. 50+ metadata consideration points including deadlines and lead times. Links to author submission guides fast and easy. Request a demo. htt...

Join us for a focused discussion on early phase clinical trial strategies in neurodegenerative disease therapeutics. This session hosted by ASCPT will explore key considerations and share examples from studies in neurode...

ICON is at the World Drug Safety Congress in Boston. Visit us at booth \#227 to learn how ICON is advancing innovation in drug safety and pharmacovigilance. Our experts will share insights on risk management, patient s...

Recently, 132 of ICON’s biopharma sponsors shared insights on the evolution of clinical monitoring. Our new whitepaper highlights the benefits: faster enrolment, reduced site burden and strategic CRA support. Read more: ...

Recently, 132 of ICON’s biopharma sponsors shared insights on the evolution of clinical monitoring. Our new whitepaper highlights the benefits: faster enrolment, reduced site burden and strategic CRA support. Read more: ...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...